ScHARR-TAG have had a new NICE STA topic confirmed. It is rivaroxaban (Xarelto, Bayer) for the treatment of acute coronary syndrome.
The draft scope is available (here). It highlights two patient groups with different comparators. For people who are to be managed with PCI; bivalirudin in combination with aspirin and clopidogrel, prasugrel in combination with aspirin, and ticagrelor in combination with aspirin (subject to ongoing NICE technology appraisal). For people who are not to be managed with PCI; clopidogrel in combination with aspirin, and ticagrelor in combination with aspirin (subject to ongoing NICE technology appraisal).
